[go: up one dir, main page]

CY1116383T1 - Αντιβακτηριακες ενωσεις - Google Patents

Αντιβακτηριακες ενωσεις

Info

Publication number
CY1116383T1
CY1116383T1 CY20151100440T CY151100440T CY1116383T1 CY 1116383 T1 CY1116383 T1 CY 1116383T1 CY 20151100440 T CY20151100440 T CY 20151100440T CY 151100440 T CY151100440 T CY 151100440T CY 1116383 T1 CY1116383 T1 CY 1116383T1
Authority
CY
Cyprus
Prior art keywords
compounds
antibacterial compounds
infections
treatment
diseases
Prior art date
Application number
CY20151100440T
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Therapeutics Plc filed Critical Summit Therapeutics Plc
Publication of CY1116383T1 publication Critical patent/CY1116383T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Αποκαλύπτονται ενώσεις του τύπου (I), οι οποίες χρησιμοποιούνται στην θεραπεία βακτηριακών ασθενειών και μολύνσεων, σε συνθέσεις που περιέχουν αυτές τις ενώσεις και σε μεθόδους θεραπείας των βακτηριακών ασθενειών και μολύνσεων με τη χρήση των ενώσεων. Ειδικότερα δε, οι ενώσεις είναι χρήσιμες για τη θεραπεία της μόλυνσης με, και ασθενειών που προκαλούνται από, το Clostridium difficile.
CY20151100440T 2008-12-02 2015-05-15 Αντιβακτηριακες ενωσεις CY1116383T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
EP09795514.0A EP2373631B1 (en) 2008-12-02 2009-12-01 Antibacterial compounds

Publications (1)

Publication Number Publication Date
CY1116383T1 true CY1116383T1 (el) 2017-02-08

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100440T CY1116383T1 (el) 2008-12-02 2015-05-15 Αντιβακτηριακες ενωσεις
CY20161100572T CY1117934T1 (el) 2008-12-02 2016-06-24 Αντιβακτηριακες φαρμακευτικες συνθεσεις

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161100572T CY1117934T1 (el) 2008-12-02 2016-06-24 Αντιβακτηριακες φαρμακευτικες συνθεσεις

Country Status (28)

Country Link
US (3) US8975416B2 (el)
EP (3) EP3095783A1 (el)
JP (3) JP5665756B2 (el)
KR (1) KR101643435B1 (el)
CN (1) CN102227411B (el)
AU (1) AU2009323854B2 (el)
BR (2) BRPI0922220B8 (el)
CA (1) CA2744962C (el)
CY (2) CY1116383T1 (el)
DK (2) DK2907813T3 (el)
ES (2) ES2537059T3 (el)
GB (1) GB0821913D0 (el)
HK (2) HK1162169A1 (el)
HR (2) HRP20150518T1 (el)
HU (1) HUE029151T2 (el)
IL (1) IL213325A (el)
LT (1) LT2907813T (el)
MX (1) MX2011005837A (el)
NZ (1) NZ593111A (el)
PL (2) PL2373631T3 (el)
PT (2) PT2907813T (el)
RS (1) RS54904B1 (el)
RU (1) RU2525915C2 (el)
SG (1) SG171939A1 (el)
SI (2) SI2907813T1 (el)
SM (2) SMT201500117B (el)
WO (1) WO2010063996A2 (el)
ZA (1) ZA201103751B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
AU2011260097B2 (en) 2010-06-01 2015-01-22 Summit (Oxford) Limited Compounds for the treatment of clostridium difficile associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
PT3628161T (pt) 2012-11-23 2023-05-15 Seres Therapeutics Inc Composições bacterianas sinergísticas e métodos de produção e utilização das mesmas
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3587558A3 (en) 2013-02-04 2020-03-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CA2931317C (en) 2013-11-25 2023-08-22 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
CN111315736B (zh) * 2017-10-05 2023-07-07 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
EP3999502A1 (en) 2019-07-17 2022-05-25 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
CN114945566B (zh) 2019-12-06 2024-11-12 沃泰克斯药物股份有限公司 作为钠通道调节剂的取代四氢呋喃
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
PE20240768A1 (es) * 2021-05-24 2024-04-17 Aimmax Therapeutics Inc Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas
IL308953A (en) 2021-06-04 2024-01-01 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4334298A1 (en) 2021-06-14 2024-03-13 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
EP4398890A2 (en) 2021-09-09 2024-07-17 Ernesto Abel-Santos Inhibitors of c. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (el) * 1974-04-30 1975-11-11
JPS50154250A (el) * 1974-05-31 1975-12-12
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
CA2204639A1 (en) * 1994-11-17 1996-05-30 Werner Leupin Antibacterial dibenzimidazole derivatives
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
MXPA03004655A (es) 2000-11-27 2003-09-04 Ciba Sc Holding Ag Derivados 5-aril y 5-heteroaril-2-(2-hidroxifenil)-2h-benzotriazol substituidos como absorbentes de uv.
MY138797A (en) 2000-12-15 2009-07-31 Vertex Pharma Bacterial gyrase inhibitors and uses thereof
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
WO2003105846A1 (en) 2002-06-13 2003-12-24 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
JPWO2004035522A1 (ja) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
AU2003291226B2 (en) 2002-11-01 2009-06-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) * 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
ES2354824T3 (es) 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
CA2617123C (en) 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
EP2121626A1 (en) 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazole derivatives
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
HUE027964T2 (en) 2009-04-02 2016-11-28 Fund Centro Nac De Investig Oncologicas Carlos Iii Imidazo [2,1-b] [1,3,4] thiadiazole derivatives
CA2763624A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
ES2632220T3 (es) 2009-06-15 2017-09-11 Rigel Pharmaceuticals, Inc. Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK)
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
AU2011260097B2 (en) 2010-06-01 2015-01-22 Summit (Oxford) Limited Compounds for the treatment of clostridium difficile associated disease

Also Published As

Publication number Publication date
DK2907813T3 (en) 2016-07-25
JP2012510458A (ja) 2012-05-10
DK2373631T3 (en) 2015-05-26
PT2907813T (pt) 2016-08-05
JP5665756B2 (ja) 2015-02-04
US20120020950A1 (en) 2012-01-26
BRPI0922220B8 (pt) 2021-05-25
US20160184283A1 (en) 2016-06-30
ES2575908T3 (es) 2016-07-04
PL2373631T3 (pl) 2015-10-30
EP2373631A2 (en) 2011-10-12
RU2525915C2 (ru) 2014-08-20
US20150150861A1 (en) 2015-06-04
CN102227411B (zh) 2015-10-14
BRPI0922220A2 (pt) 2015-12-29
PT2373631E (pt) 2015-06-09
BR122020013025B1 (pt) 2021-05-18
JP2015078220A (ja) 2015-04-23
JP2017048217A (ja) 2017-03-09
RU2011127165A (ru) 2013-01-10
SMT201500117B (it) 2015-07-09
EP2907813B1 (en) 2016-04-27
US9314456B2 (en) 2016-04-19
NZ593111A (en) 2013-05-31
CY1117934T1 (el) 2017-05-17
US8975416B2 (en) 2015-03-10
CA2744962A1 (en) 2010-06-10
SG171939A1 (en) 2011-07-28
KR101643435B1 (ko) 2016-07-27
SI2907813T1 (sl) 2016-09-30
IL213325A0 (en) 2011-07-31
WO2010063996A3 (en) 2010-12-29
AU2009323854A2 (en) 2011-06-30
SMT201600259B (it) 2016-08-31
EP3095783A1 (en) 2016-11-23
WO2010063996A2 (en) 2010-06-10
SI2373631T1 (sl) 2015-08-31
HUE029151T2 (hu) 2017-02-28
EP2907813A1 (en) 2015-08-19
KR20110093925A (ko) 2011-08-18
US9763925B2 (en) 2017-09-19
HRP20150518T1 (hr) 2015-07-17
BRPI0922220A8 (pt) 2018-04-03
AU2009323854A1 (en) 2010-06-10
IL213325A (en) 2016-02-29
MX2011005837A (es) 2011-11-18
PL2907813T3 (pl) 2016-09-30
RS54904B1 (sr) 2016-10-31
LT2907813T (lt) 2016-10-10
HK1208668A1 (zh) 2016-03-11
HRP20160597T1 (hr) 2016-09-23
EP2373631B1 (en) 2015-02-25
CA2744962C (en) 2017-06-06
ES2537059T3 (es) 2015-06-02
ZA201103751B (en) 2014-10-29
CN102227411A (zh) 2011-10-26
GB0821913D0 (en) 2009-01-07
BRPI0922220B1 (pt) 2021-03-09
HK1162169A1 (en) 2012-08-24
AU2009323854B2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CY1116383T1 (el) Αντιβακτηριακες ενωσεις
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1119660T1 (el) Antibakthpiakh απο toy στοματος συνθεση
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
EA201170772A1 (ru) Органические соединения
CY1117409T1 (el) Παραγωγα γλυκοσιδιου και η χρηση τους
EA201100447A1 (ru) Органические соединения
CR11861A (es) Compuestos organicos
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
SG178952A1 (en) Chemical compounds
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
EA201791850A1 (ru) Борсодержащие малые молекулы
CY1116436T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
EA201101477A1 (ru) Органические соединения и их применение
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
EA201390639A1 (ru) Производные 2-пиперазин-1-ил-4н-1,3-бензотиазин-4-она и их применение для лечения инфекций у млекопитающих
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
CY1114883T1 (el) Καινοφανεις αντιβακτηριακοι παραγοντες για την αγωγη των κατα gram θετικων λοιμωξεων
CY1118371T1 (el) Αναστολεις του iap
PA8855001A1 (es) Monocarbamas
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório